Cargando…
Endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from ANGEL-ACT registry
OBJECTIVES: To investigate the safety and efficacy of endovascular treatment (EVT) for acute medium vessel occlusion (MeVO) in the anterior circulation and to explore the independent predictors of the 90-day good outcome for such patients. METHODS: Data from ANGEL-ACT Registry were analysed in our s...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985797/ https://www.ncbi.nlm.nih.gov/pubmed/36219803 http://dx.doi.org/10.1136/svn-2022-001561 |
_version_ | 1784901030181339136 |
---|---|
author | Sun, Dapeng , Raynald Huo, Xiaochuan Jia, Baixue Tong, Xu Wang, Anxin Ma, Gaoting Ma, Ning Gao, Feng Mo, Dapeng Miao, Zhongrong |
author_facet | Sun, Dapeng , Raynald Huo, Xiaochuan Jia, Baixue Tong, Xu Wang, Anxin Ma, Gaoting Ma, Ning Gao, Feng Mo, Dapeng Miao, Zhongrong |
author_sort | Sun, Dapeng |
collection | PubMed |
description | OBJECTIVES: To investigate the safety and efficacy of endovascular treatment (EVT) for acute medium vessel occlusion (MeVO) in the anterior circulation and to explore the independent predictors of the 90-day good outcome for such patients. METHODS: Data from ANGEL-ACT Registry were analysed in our study. The outcomes, such as the modified Rankin Scale (mRS) at 90 days, successful recanalisation rate and symptomatic intracranial haemorrhage (SICH) rate, were compared between MeVO and acute large vessel occlusions (LVO). Then, the independent predictors of the good outcome at 90 days in MeVO patients were determined by the logistic regression analyses. RESULTS: We included 1032 subjects in the analysis, of which, 147 were MeVO and 885 were LVO. mRS at 90 days distribution (3 (0–4) vs 3 (0–5), common odds ratio (OR) =1.00, 95% confidence interval (CI) 0.73 to 1.38, p=0.994), SICH rate (4.8% vs 8.9%; OR=0.59, 95% CI 0.26 to 1.34, p=0.205) and successful recanalisation rate (89.8% vs 89.7%; OR=1.00 95% CI 0.51 to 1.93, p=0.992) were similar between the MeVO and LVO groups after adjusting for the confounders. We identified that baseline neutrophil-to-lymphocyte ratio ≤4.1 (OR=2.13, 95% CI 1.14 to 3.99, p=0.019), baseline National Institutes of Health Stroke Scale ≤14 (OR=1.96, 95% CI 1.02 to 3.80, p=0.045) and mechanical thrombectomy passes ≤1 (OR=2.16, 95% CI 1.14 to 4.11, p=0.021) were independent predictors of the 90-day good outcome in MeVO patients undergoing EVT. CONCLUSIONS: Patients with MeVO achieved similar 90-day mRS, SICH rate and successful recanalisation rate after EVT compared with patients with LVO. Several independent predictors of 90-day good outcome in MeVO patients undergoing EVT were determined, which should be highly considered in MeVO stroke management. |
format | Online Article Text |
id | pubmed-9985797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-99857972023-03-06 Endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from ANGEL-ACT registry Sun, Dapeng , Raynald Huo, Xiaochuan Jia, Baixue Tong, Xu Wang, Anxin Ma, Gaoting Ma, Ning Gao, Feng Mo, Dapeng Miao, Zhongrong Stroke Vasc Neurol Original Research OBJECTIVES: To investigate the safety and efficacy of endovascular treatment (EVT) for acute medium vessel occlusion (MeVO) in the anterior circulation and to explore the independent predictors of the 90-day good outcome for such patients. METHODS: Data from ANGEL-ACT Registry were analysed in our study. The outcomes, such as the modified Rankin Scale (mRS) at 90 days, successful recanalisation rate and symptomatic intracranial haemorrhage (SICH) rate, were compared between MeVO and acute large vessel occlusions (LVO). Then, the independent predictors of the good outcome at 90 days in MeVO patients were determined by the logistic regression analyses. RESULTS: We included 1032 subjects in the analysis, of which, 147 were MeVO and 885 were LVO. mRS at 90 days distribution (3 (0–4) vs 3 (0–5), common odds ratio (OR) =1.00, 95% confidence interval (CI) 0.73 to 1.38, p=0.994), SICH rate (4.8% vs 8.9%; OR=0.59, 95% CI 0.26 to 1.34, p=0.205) and successful recanalisation rate (89.8% vs 89.7%; OR=1.00 95% CI 0.51 to 1.93, p=0.992) were similar between the MeVO and LVO groups after adjusting for the confounders. We identified that baseline neutrophil-to-lymphocyte ratio ≤4.1 (OR=2.13, 95% CI 1.14 to 3.99, p=0.019), baseline National Institutes of Health Stroke Scale ≤14 (OR=1.96, 95% CI 1.02 to 3.80, p=0.045) and mechanical thrombectomy passes ≤1 (OR=2.16, 95% CI 1.14 to 4.11, p=0.021) were independent predictors of the 90-day good outcome in MeVO patients undergoing EVT. CONCLUSIONS: Patients with MeVO achieved similar 90-day mRS, SICH rate and successful recanalisation rate after EVT compared with patients with LVO. Several independent predictors of 90-day good outcome in MeVO patients undergoing EVT were determined, which should be highly considered in MeVO stroke management. BMJ Publishing Group 2022-09-01 /pmc/articles/PMC9985797/ /pubmed/36219803 http://dx.doi.org/10.1136/svn-2022-001561 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Sun, Dapeng , Raynald Huo, Xiaochuan Jia, Baixue Tong, Xu Wang, Anxin Ma, Gaoting Ma, Ning Gao, Feng Mo, Dapeng Miao, Zhongrong Endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from ANGEL-ACT registry |
title | Endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from ANGEL-ACT registry |
title_full | Endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from ANGEL-ACT registry |
title_fullStr | Endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from ANGEL-ACT registry |
title_full_unstemmed | Endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from ANGEL-ACT registry |
title_short | Endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from ANGEL-ACT registry |
title_sort | endovascular treatment for acute ischaemic stroke due to medium vessel occlusion: data from angel-act registry |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985797/ https://www.ncbi.nlm.nih.gov/pubmed/36219803 http://dx.doi.org/10.1136/svn-2022-001561 |
work_keys_str_mv | AT sundapeng endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT raynald endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT huoxiaochuan endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT jiabaixue endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT tongxu endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT wanganxin endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT magaoting endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT maning endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT gaofeng endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT modapeng endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry AT miaozhongrong endovasculartreatmentforacuteischaemicstrokeduetomediumvesselocclusiondatafromangelactregistry |